Spero Therapeutics SPRO is preparing to release its quarterly earnings on Thursday, 2024-11-14. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Spero Therapeutics to report an earnings per share (EPS) of $-0.50.
The announcement from Spero Therapeutics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
Past Earnings Performance
Last quarter the company beat EPS by $0.05, which was followed by a 5.22% drop in the share price the next day.
Here's a look at Spero Therapeutics's past performance and the resulting price change:
| Quarter | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| EPS Estimate | -0.38 | -0.04 | -0.10 | -0.03 |
| EPS Actual | -0.33 | -0.24 | 0.96 | -0.06 |
| Price Change % | -5.0% | -3.0% | 5.0% | -2.0% |
Tracking Spero Therapeutics's Stock Performance
Shares of Spero Therapeutics were trading at $1.32 as of November 12. Over the last 52-week period, shares are up 13.36%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
To track all earnings releases for Spero Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
